Study Demonstrates Glysure System’s Ability to Accurately Measure Blood Glucose Levels in the ICU
Primary investigator presents results at the World Federation of Societies of Intensive and Critical Care Medicine (WFSICCM) Congress
OXFORD, England, August 28, 2013 /PRNewswire/ –
GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM)
systems, today announced that a study demonstrating the effectiveness of its technology in
continuously measuring blood glucose levels in post-surgical cardiac surgery patients will
be presented at the World Federation of Societies of Intensive and Critical Care Medicine
(WFSICCM) Congress being held this week in Durban, South Africa.
For the study, Use of an intravascular continuous blood glucose sensor during post
operative ICU care of cardiac surgery patients, researchers used the GlySure CBGM system
to measure blood glucose concentrations in 24 post cardiac surgery ICU patients
continuously and in real-time. Blood samples were taken at regular intervals and the
glucose concentrations measured. At the time of sampling, the GlySure monitor was time
stamped to allow subsequent statistical analysis between the continuous GlySure sensor and
the intermittent glucose values.
The researchers found glucose concentrations measured by the GlySure system correlated
with the concentrations measured in the blood draws. They concluded the system can
dramatically reduce the need for frequent intermittent sampling and offers the potential
for early identification of hypoglycemic and hyperglycaemic excursions.
“We are excited by these results,” said Principal Investigator Dr. Krishna Prasad. “A
device like this would be extremely valuable in managing these kinds of patients in the
ICU. The system is also easy to set up and use, which are key requirements in critical
GlySure recently commenced a multi-center CE Trial on cardiac surgery patients, which
the company expects to complete this fall.
GlySure has developed a continuous intravascular glucose monitoring system using a
proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for
implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).
The company has demonstrated through ICU testing highly accurate sensors which can provide
continuous glucose readings throughout the length of a patient’s stay in the ICU. GlySure
was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 30
employees. The company’s products are not approved for use in the U.S. or Europe.
Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870. firstname.lastname@example.org. Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127. email@example.com
SOURCE GlySure Limited